Guangzhou Baiyunshan Pharmaceutical Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Guangzhou Baiyunshan Pharmaceutical Holdings has a total shareholder equity of CN¥38.1B and total debt of CN¥13.5B, which brings its debt-to-equity ratio to 35.5%. Its total assets and total liabilities are CN¥79.3B and CN¥41.2B respectively. Guangzhou Baiyunshan Pharmaceutical Holdings's EBIT is CN¥3.9B making its interest coverage ratio -20.6. It has cash and short-term investments of CN¥17.5B.
Key information
35.5%
Debt to equity ratio
CN¥13.50b
Debt
| Interest coverage ratio | -20.6x |
| Cash | CN¥17.47b |
| Equity | CN¥38.05b |
| Total liabilities | CN¥41.20b |
| Total assets | CN¥79.26b |
Recent financial health updates
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Feb 04
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Feb 04There Are Reasons To Feel Uneasy About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Jan 07Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Financial Position Analysis
Short Term Liabilities: 874's short term assets (CN¥53.1B) exceed its short term liabilities (CN¥36.3B).
Long Term Liabilities: 874's short term assets (CN¥53.1B) exceed its long term liabilities (CN¥4.9B).
Debt to Equity History and Analysis
Debt Level: 874 has more cash than its total debt.
Reducing Debt: 874's debt to equity ratio has increased from 28.2% to 35.5% over the past 5 years.
Debt Coverage: 874's debt is not well covered by operating cash flow (18.2%).
Interest Coverage: 874 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 00:37 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is covered by 27 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| null null | BOCI Research Ltd. |
| Sandra Sun | BofA Global Research |